Publications

Professor Rob Coleman

Wilson C., Holen I., Coleman R.E. (2012) Seed, soil and secreted hormones: potential interactions of breast cancer cells with their endocrine/paracrine microenvironment and implications for treatment with bisphosphonates. Cancer Treatment Reviews 38(7): p. 877-89.

Hadji P., Gnant M., Body JJ., Bundred NJ., Brufsky A., Coleman RE., Guise TA., Lipton A., Aapro MS. (2012) Cancer Treatment-induced bone loss in premenopausal women: A need for therapeutic intervention? Cancer Treatment Reviews 38: 798-806.

Berruti A., Cook R., Saad F., Buttigliero C., Lipton A., Tampellini M., Lee K-A., ColemaN RE., Smith MR. (2012) Prognostic role of serum parathyroid hormone levels in advanced prostate cancer patients undergoing zoledronic acid administration. The Oncologist 17: 645-652.

Brown HK., Ottewell PD., Evans CA., Coleman RE., Holen I. (2012) A single administration of combination therapy inhibits breast tumour progression in bone and modifies both osteoblasts and osteoclasts. Journal of Bone Oncology 1, 47–56.

Hadji P., Coleman R., Gnant M., Green J. (2012) The impact of menopause on bone, zoledronic acid, and implications for breast cancer growth and metastasis. Annals of Oncology 23(11):2782-90.

Coleman R., Gnant M., Morgan G., Clezardin P. (2012) Effects of bone-targeted agents on cancer progression and mortality. Journal of National Cancer Institute 104: 1059-1067.

Coleman RE. Adjuvant bone-targeted therapy to prevent metastasis: lessons from the AZURE study. Curr. Opin Support Palliat Care 6: 322-329, 2012.

Brown JE, Cook R,, Lipton A., Coleman R.E. (2012) Serum Lactate Dehydrogenase Is Prognostic for Survival in Patients With Bone Metastases From Breast Cancer: A Retrospective Analysis in Bisphosphonate-Treated Patients. Clin Cancer Res Sep 4. [Epub ahead of print].

Coleman RE., De Boer R., Eidtmann H., Llombart-Cussac A., Davidson N., Neven P., von Minckwitz G., Sleeboom H, Forbes J., Barrios C., Frassoldatis A., Campbell I, Paija O., Martin N., Modi A., Bundred N. (2012) Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Annals of Oncology Oct 9. [Epub ahead of print].

Lester JE., Dodwell D., Brown JE, Purohit OP, Gutcher SA., Ellis S., Thorpe R., Horsman JM., Coleman RE. (2012) Prevention of anastrozole induced bone loss with monthly oral ibandronate: Final 5 year results from the ARIBON trial. Journal of Bone Oncology 1:57–62.